European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

First Irreversible Proteasome Inhibitor for Relapsed Multiple Myeloma Approved in the European Union. Approval Based on Data From Pivotal Phase 3 ASPIRE Trial Which Demonstrated Patients Treated With Kyprolis in Combination Lived Nearly Nine Months Longer Without Disease Progression Compared to Common Treatment Course.

Source: International Myeloma Foundation - November 18, 2015 Category: Hematology Source Type: news